- Home
- NTLA vs MXL Comparison
NTLA vs MXL Comparison
Compare NTLA & MXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- MXL
- Stock Information
- Founded
- NTLA 2014
- MXL 2003
- Country
- NTLA United States
- MXL United States
- Employees
- NTLA N/A
- MXL N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MXL Semiconductors
- Sector
- NTLA Health Care
- MXL Technology
- Exchange
- NTLA Nasdaq
- MXL Nasdaq
- Market Cap
- NTLA 710.1M
- MXL N/A
- IPO Year
- NTLA 2016
- MXL 2010
- Fundamental
- Price
- NTLA $8.28
- MXL $11.22
- Analyst Decision
- NTLA Buy
- MXL Buy
- Analyst Count
- NTLA 19
- MXL 8
- Target Price
- NTLA $38.47
- MXL $20.21
- AVG Volume (30 Days)
- NTLA 3.1M
- MXL 1.6M
- Earning Date
- NTLA 05-08-2025
- MXL 04-23-2025
- Dividend Yield
- NTLA N/A
- MXL N/A
- EPS Growth
- NTLA N/A
- MXL N/A
- EPS
- NTLA N/A
- MXL N/A
- Revenue
- NTLA $45,569,000.00
- MXL $361,192,000.00
- Revenue This Year
- NTLA N/A
- MXL $24.43
- Revenue Next Year
- NTLA N/A
- MXL $19.74
- P/E Ratio
- NTLA N/A
- MXL N/A
- Revenue Growth
- NTLA N/A
- MXL N/A
- 52 Week Low
- NTLA $5.90
- MXL $8.35
- 52 Week High
- NTLA $28.18
- MXL $26.59
- Technical
- Relative Strength Index (RSI)
- NTLA 51.86
- MXL 53.76
- Support Level
- NTLA $7.21
- MXL $10.16
- Resistance Level
- NTLA $9.27
- MXL $10.75
- Average True Range (ATR)
- NTLA 0.65
- MXL 0.56
- MACD
- NTLA 0.02
- MXL 0.24
- Stochastic Oscillator
- NTLA 53.33
- MXL 81.44
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.